• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Performance of 4 Automated SARS-CoV-2 Serology Assay Platforms in a Large Cohort Including Susceptible COVID-19-Negative and COVID-19-Positive Patients

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Ward, Matthew D
    Mullins, Kristin E
    Pickett, Elizabeth
    Merrill, VeRonika
    Ruiz, Mark
    Rebuck, Heather
    Duh, Show-Hong
    Christenson, Robert H
    Date
    2021-03-10
    Journal
    Journal of Applied Laboratory Medicine
    Publisher
    Oxford University Press
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1093/jalm/jfab014
    https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33693808/
    Abstract
    BACKGROUND: Anti-SARS-CoV-2 serological responses may have a vital role in controlling the spread of the disease. However, the comparative performance of automated serological assays has not been determined in susceptible patients with significant comorbidities. METHODS: In this study, we used large numbers of samples from patients who were negative (n = 2030) or positive (n = 112) for COVID-19 to compare the performance of 4 serological assay platforms: Siemens Healthineers Atellica IM Analyzer, Siemens Healthineers Dimension EXL Systems, Abbott ARCHITECT, and Roche cobas. RESULTS: All 4 serology assay platforms exhibited comparable negative percentage of agreement with negative COVID-19 status ranging from 99.2% to 99.7% and positive percentage of agreement from 84.8% to 87.5% with positive real-time reverse transcriptase PCR results. Of the 2142 total samples, only 38 samples (1.8%) yielded discordant results on one or more platforms. However, only 1.1% (23/2030) of results from the COVID-19-negative cohort were discordant. whereas discordance was 10-fold higher for the COVID-19-positive cohort, at 11.3% (15/112). Of the total 38 discordant results, 34 were discordant on only one platform. CONCLUSIONS: Serology assay performance was comparable across the 4 platforms assessed in a large population of patients who were COVID-19 negative with relevant comorbidities. The pattern of discordance shows that samples were discordant on a single assay platform, and the discordance rate was 10-fold higher in the population that was COVID-19 positive.
    Rights/Terms
    © American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.
    Keyword
    COVID-19
    SARS-CoV-2
    automated platforms
    serology
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/16405
    ae974a485f413a2113503eed53cd6c53
    10.1093/jalm/jfab014
    Scopus Count
    Collections
    UMB Coronavirus Publications
    UMB Open Access Articles

    entitlement

    Related articles

    • Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2.
    • Authors: Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, McLawhon RW, Voss JE, Nemazee D, Fitzgerald RL
    • Issue date: 2021 Jan 30
    • Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-2 for Use in Clinical Laboratories.
    • Authors: Plaga A, Wei R, Olson E, Payto D, Harrington J, Nwe-Kissig PT, Strizzi M, Zilka S, Ko J, Colón-Franco JM
    • Issue date: 2021 Jul 7
    • Analytical and Clinical Analysis of Two Automated Anti-SARS-CoV-2 Immunoassays in Pre-Pandemic and Pandemic Patient Populations.
    • Authors: Yang J, Pederson EC, Hamilton C, Neibauer T, Robyak K, McGhee P, Speicher T, Zhu Y
    • Issue date: 2021 Mar 1
    • Assessment of commercial SARS-CoV-2 antibody assays, Jamaica.
    • Authors: Butterfield TR, Bruce-Mowatt A, Phillips YZR, Brown N, Francis K, Brown J, Walker JP, McKnight NAL, Ehikhametalor K, Taylor DK, Bruce CA, McGrowder D, Wharfe G, Sandiford SL, Thompson TK, Anzinger JJ
    • Issue date: 2021 Apr
    • Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies.
    • Authors: Hubbard JA, Geno KA, Khan J, Szczepiorkowski ZM, de Gijsel D, Ovalle AA, AlSalman AS, Gallagher TL, Johnston AA, Tibbetts AR, Vital SE, Cervinski MA, Nerenz RD
    • Issue date: 2021 Mar 1
    DSpace software (copyright © 2002 - 2022)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.